Allergan (AGN) Receives FDA Approval for OZURDEX(TM)
More News related to AGN
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
More News related to FDA
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
- Cowen & Co Downgrades Smith & Wesson (SWHC) to Neutral
- MKM Partners Downgrades Take-Two Interactive (TTWO) to Neutral
- Cowen & Co Downgrades Take-Two Interactive (TTWO) to Neutral
Allergan, Inc. (NYSE: AGN) today announced that the United States FDA has approved OZURDEX(TM) (dexamethasone intravitreal implant) 0.7 mg as the first drug therapy indicated for the treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion. Retinal vein occlusion, including BRVO and CRVO, is the second most common retinal vascular disease after diabetic retinopathy1 and is a significant cause of vision loss.
More from the release.
Related Categories
FDAStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
